Dr. Ksenija Slavic Obradovic

We are exploring induction of cell death in cancer cells in the context of treatment with SMAC (Second mitochondrial activator of caspase) mimetics. SMAC mimetics facilitate cell death induction by targeting Inhibitor of Apoptosis Proteins (IAPs), a family of anti-apoptotic proteins that promote pro-survival signaling pathways and prevent the activation of caspases. However, significant heterogeneity in responses to SMAC mimetic treatment exists between cell lines originating from different tumor types and genetic background. Thus, we aim to explore the molecular mechanisms behind either sensitization or resistance mechanisms in various cellular contexts. Extending on this, we are investigating the modalities of cell death facilitated by SMAC mimetics and the associated consequences on the immune system. Importantly, cancer therapies that induce immunogenic cell death (ICD) may consequently, due to concomitant activation of the immune system and the induction of anti-tumor immunity, lead to better and long lasting clinical benefit.